Skip to contentB
Biofrontera Inc.
B
BFRIBiofrontera Inc. Q2 2024 · 10-Q
Revenue$7.84M$7.84M+34.0% vs Q2 2023 Net Income-$257.00K-$257.00KN/M vs Q2 2023 EPS Diluted-$0.05-$0.05N/M vs Q2 2023 Operating Income-$5,071,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biofrontera Inc. · CIK 1858685 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,672,000N/M Margins · derivedOperating margin-64.7%+84.1 pt vs Q2 2023
Net margin-3.3%+164.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end